Stay updated with breaking news from Classification Criteria. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The selective, allosteric tyrosine kinase 2 inhibitor demonstrated significant and clinically meaningful improvements in PROs versus placebo in a phase 2 trial of patients with PsA.
The debate persists as to whether these conditions are on the same spectrum or should be separated.
At week 52, 58.5% of patients continuing risankizumab treatment and 55.7% of patients who switched to risankizumab at week 24 achieved ACR20.
Data from the BE VITAL OLE study, which included patients from the BE COMPLETE and BE OPTIMAL studies, suggests the benefits of bimekizumab in patients with psoriatic arthritis with inadequate response or intolerance to TNF inhibitors were sustained for up to 52 weeis.
New research found that certain systemic markers in psoriatic arthritis and psoriasis patients correlated with PASI scores, indicating the clinical relevance of platelets and neutrophils in inflammation.